Brighter teams up with Sanmina to manufacture Actiste.
Brighter today announced a partnership with Sanmina to produce the first generation of Actiste®, a connected diabetes device that allows users to monitor blood sugar, inject insulin and log blood sugar levels and insulin doses in a single device. Sanmina is a global Tier 1 provider of integrated manufacturing solutions, making some of the world’s most complex and innovative electronic and mechanical products.
Essential criteria in Brighter’s selection included Sanmina’s substantial experience producing advanced medical devices including millions of diabetes care tools. Sanmina’s comprehensive product launch and manufacturing capabilities in Sweden, global footprint, ISO 13485 certified manufacturing capabilities and ability to scale were also key considerations. Through this collaboration Brighter will be able to launch Actiste efficiently on the global market.
Actiste simplifies insulin-treated diabetes by collecting all the key features in a connected device that can measure blood glucose levels, dose and inject insulin, as well as store and share information. The information logged can automatically be shared with relatives or healthcare providers, via a built-in internet connection.
“Sanmina has extensive medical NPI and manufacturing expertise here in Sweden and is a leading manufacturer of a wide range of medical devices including products for the monitoring and treatment of diabetes. Their experience and familiarity with high technology medical devices provides us with confidence for our launch of Actiste,” says Truls Sjöstedt, CEO at Brighter. “With Sanmina as a partner, we will be able to scale up manufacturing to meet global demand, and optimize market access in many key geographies.”
With a reliable manufacturing partner as well as the first telecom operator agreement in place, the Actiste team can now shift focus, leaving the development phase and entering the production preparation phase where a vital component is to finalize the detailed launch plan for Actiste. With Actiste, Brighter is initially targeting markets in Northern Europe, where the company recently signed an agreement with Telia Company for Sweden, and South-East Asia, where Brighter is currently negotiating partnerships with multiple leading telecom network operators.
”Sanmina is pleased to partner with Brighter and support the development of a high technology medical device here in Sweden. Local support during the prototype, new product introduction and product launch stage and the ability to scale volume production globally is part of the value we provide to customers.” says Tord Berggren, Vice President and Plant Manager at Sanmina in Sweden.
Questions? Please contact:
Henrik Norström, COO
Phone: +46 733 40 30 45
Truls Sjöstedt, CEO
Phone: +46 709 73 46 00
Sanmina, is a leading manufacturer of medical products for some of the world’s best known healthcare companies. The company has a strong audit history with the FDA, ISO 13485 certified and complies with other applicable local regulations. Sanmina’s gateway facilities provide end-to-end solutions including PCB and system design, quick turn prototyping, product introduction, system integration and global order fulfillment. Sanmina’s engineers work with customers to design, test and validate products resulting in faster time to market and more robust products. Sanmina operates in 25 countries on six continents. Customers benefit from having Sanmina facilities nearby for engineering and product launch, along with a global footprint for manufacturing and logistics.
About Brighter AB (publ)
Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and innovative tools, jDome® and Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care and care for the elderly, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms.
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CET on July 7 2016.